The use of real-world evidence to generate cost analysis of antibiotic susceptibility testing (AST) in patients with treatment failure in Thailand: A large population-based study.

BACKGROUND

eradication is effective for gastric cancer prevention. Treatment failure is caused by increased antibiotic resistance. This study aimed to determine eradication rates and perform cost analysis between susceptibility-guided therapy and empirical treatment in patients with treatment failure.

METHODS

This retrospective cohort study included patients with dyspepsia undergoing gastroscopy at tertiary care center in Thailand from March 2014 to October 2021. Treatment failure was defined as persistent infection after ≥1 regimen completion. Early AST was defined as AST performed shortly after first-line treatment failure. Demographic data, AST results, eradication regimens, and medication costs were collected from database and reviewed.

RESULTS

Of 1080 patients with infection, 315 had treatment failure (mean age 58.4 years; 44.4 % males). AST of 85 strains demonstrated resistance to levofloxacin (57.6 %), metronidazole (51.8 %), clarithromycin (44.7 %), and amoxicillin (4.7 %). In multivariate analysis, sequential therapy was significantly associated with treatment failure (OR 1.66; 95%CI 1.01-2.74, p = 0.045), whereas vonoprazan-containing therapy was related to treatment success (OR 1.60; 95%CI 1.04-2.48, p = 0.034). Medication nonadherence (OR 37.97; 95%CI 8.97-160.65, p < 0.001) contributed to treatment failure. Susceptibility-guided therapy provided better eradication rate than empirical therapy (97.5% vs. 65.5 %, OR 20.54; 95%CI 4.92-85.81, p < 0.001) in treatment failure group. Twenty-four patients had early AST, while 61 had AST after treatment failures. Most patients with early AST achieved treatment success by second-line eradication. Early AST provided significantly lower total average cost of treatment than group without AST ($368.2 vs. $402.0 per patient, p = 0.034) and AST after treatment failures ($368.2 vs. $752.8 per patient, p < 0.001). Early AST group had the lowest cost of subsequent medication, posttreatment urea breath test, and hospital visits.

CONCLUSION

Susceptibility-guided therapy provided significantly higher eradication rate than empirical therapy in patients with treatment failure. Early AST might be a cost-effective strategy for eradication after failed therapy and can prevent unnecessary antibiotic use in Thailand.